版本:
中国

BRIEF-Allergan and Paratek announce positive results from two phase 3 trials

March 27 Paratek Pharmaceuticals Inc:

* Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne

* Paratek Pharmaceuticals - two phase 3 trials of sarecycline for treatment of moderate to severe acne met their 12 week primary efficacy endpoints

* Paratek Pharmaceuticals says Allergan plans to file a new drug application (NDA) to U.S. Food & Drug Administration (FDA) in second half of this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐